Scholarlink

<p>Current transcatheter aortic valve implantation (TAVI) systems use glutaraldehyde-fixed tissue leaflets, which are prone to structural valve degeneration. Polymeric valves may improve durability, hemocompatibility, and manufacturability. We designed, produced, and evaluated a self-expanding nitinol-framed TAVI device with siloxane poly(urethane-urea) (SiPUU) leaflets and an electrospun SiPUU skirt. Bench testing included frame fatigue to 200 million cycles, hydrodynamics per ISO 5840-3, and flow visualization using particle image velocimetry. Biocompatibility was assessed per ISO 10993. Preclinical evaluation involved nine ovine implants with serial imaging and histology to 90 days. In vitro tests showed EOAs of 1.3–1.5 cm² and 1.7–2.1 cm² (21 and 24 mm annulus, respectively, simulating under expansion), regurgitant fraction &lt;6%, and preserved coaptation. Six animals completed follow-up with stable hemodynamics, no hemolysis, no PVL at implant, and no calcification at explant. The SiPUU-based TAVI demonstrated favorable durability, hydrodynamics, and biocompatibility, supporting further testing and delivery refinement toward first-in-human evaluation. Clinical Trial: N/A</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and preclinical results of a transcatheter aortic valve implant with novel polymeric leaflets

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月23日

查看全文
  • J. Ryan Stanfield,
  • Garrett Johnson,
  • Nelson Belais,
  • Isaac George,
  • Steven Yakubov

摘要

Current transcatheter aortic valve implantation (TAVI) systems use glutaraldehyde-fixed tissue leaflets, which are prone to structural valve degeneration. Polymeric valves may improve durability, hemocompatibility, and manufacturability. We designed, produced, and evaluated a self-expanding nitinol-framed TAVI device with siloxane poly(urethane-urea) (SiPUU) leaflets and an electrospun SiPUU skirt. Bench testing included frame fatigue to 200 million cycles, hydrodynamics per ISO 5840-3, and flow visualization using particle image velocimetry. Biocompatibility was assessed per ISO 10993. Preclinical evaluation involved nine ovine implants with serial imaging and histology to 90 days. In vitro tests showed EOAs of 1.3–1.5 cm² and 1.7–2.1 cm² (21 and 24 mm annulus, respectively, simulating under expansion), regurgitant fraction <6%, and preserved coaptation. Six animals completed follow-up with stable hemodynamics, no hemolysis, no PVL at implant, and no calcification at explant. The SiPUU-based TAVI demonstrated favorable durability, hydrodynamics, and biocompatibility, supporting further testing and delivery refinement toward first-in-human evaluation. Clinical Trial: N/A